H.C. Wainwright initiated coverage of Envoy Medical with a Buy rating and $2.50 price target. Envoy is a commercial-stage medical device company focused on the development of novel devices for patients with hearing loss, the analyst tells investors in a research note. The firm says the company's Acclaim Cochlear Implant may be the world's first fully implanted cochlear implant.
